InvestSMART

EVE Health Group Limited (ASX:EVE)

ALERT: Price-sensitive ASX Announcement for EVE
Current share price for EVE : $0.017 -0.004 (-19.05%)+
Announcement
Release
16 Jun 2026 8:21AM
Price at Release
$0.021
Full Release
download
Summary
EVE Health Group Limited, an Australian life sciences company, announced the initiation of a pilot clinical study for Libbo, their vardenafil oral soluble film for erectile dysfunction treatment. This study aims to compare Libbo's pharmacokinetic profile to an Australian-registered vardenafil tablet in fasted adult male subjects. The study's goal is to inform a subsequent pivotal bioequivalence study, essential for regulatory approval and product commercialization. The study includes patient-reported tolerability assessments targeting user experience improvements. Results are anticipated in Q3 CY2026, with potential progression to a pivotal study based on satisfactory outcomes.
Key Points
  • Initiated pilot clinical study for Libbo, a vardenafil oral soluble film.
  • Study compares Libbo to an Australian-registered vardenafil tablet.
  • Focus on fasted adult male subjects for pharmacokinetic profiling.
  • Aims to inform a pivotal bioequivalence study for regulatory approval.
  • Includes patient-reported tolerability assessments for user experience.
  • Results expected in Q3 CY2026.
  • Potential progression to pivotal study based on outcomes.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.